ICON plc | Clinical Research Organisation (CRO) for Drug Development

The evolution of FSP: not just for large pharma

How all sponsors can benefit from a synchronized outsourcing strategy

HTA guidelines for external control arms in selected European countries

Ensuring scientific rigor in external control arms

Methodologies to support HTA decision making

Practical considerations for decentralised & hybrid clinical trials

Making the transition.

Unlocking the potential of advanced therapies developed for rare diseases

How to leverage regulatory strategies and interactions with the EU EMA and the U.S. FDA to accelerate development

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

14 June 2022

Using Bayesian-based, model-assisted designs to improve dose selection in early phase oncology trials

As oncology therapeutics and early phase design models evolve, sponsors will benefit from working with a partner experienced in innovative adaptive designs for phase 1 and 2 oncology trials.

08 June 2022

Interviews with patients in clinical trials

Interviewing patients in clinical trials is a valid approach to understanding the patient perspective of a disease or treatment and provides context for interpreting quantitative clinical data.

26 May 2022

Cell and Gene Therapy: Specific Market Authorisation Guidances

Therapeutic developers may benefit from working with a partner whose regulatory expertise with CGTs will help ensure that development programmes are optimal and compliant.

25 May 2022

Why ICON is celebrating its first Inclusion Day

Inclusion Day is an opportunity for us to come together in ICON as an organisation to think about the choices we make to further inclusion and diversity.

19 May 2022

Irritable Bowel Disease (IBD): A patient’s perspective

Finding appreciation in the experience and treatment of IBD as a life-changing condition.

17 May 2022

My Clinical Research story – Jeslyne Margrette Isaac

ICON's Jeslyne Margrette Isaac shares their personal experience with clinical trials.

14 May 2022

My Clinical Research story – Lisa Linn

ICON's Lisa Linn shares their personal experience with clinical trials.

14 May 2022

My Clinical Research story – Jill Doherty

ICON's Jill Doherty shares their personal experience with clinical trials.

13 May 2022

My Clinical Research story – Ellen Dalbo

ICON's Ellen Dalbo shares their personal experience with clinical trials.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Healthcare Intelligence

The RACE for Children Act

Mainstreaming Cell & Gene Therapies

Best practices to increase engagement with medical and scientific poster content